

MARKED VERSION OF AMENDED CLAIMS - 51770

1. Use of modulators of cytokine mediated [signalling] signaling pathways in combination with integrin $\alpha_v\beta_3$ receptor antagonists for the manufacture of medicaments for the treatment or prevention of diseases.
4. Use as claimed in claim 1 [any of claims 1 to 3] wherein the modulator of cytokine mediated signalling pathways is a TNF α inhibitor.
11. Trade package, comprising as pharmaceutical agent a modulator of cytokine mediated [signalling] signaling pathways or/and an integrin $\alpha_v\beta_3$ receptor antagonist together with an instruction for use of this pharmaceutical agents in combination for simultaneous, separate, or temporal graduated application for the treatment or prevention of diseases.